Does ROPEGINTERFERON ALFA-2B Cause Off label use? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Off label use have been filed in association with ROPEGINTERFERON ALFA-2B (BESREMi). This represents 38.5% of all adverse event reports for ROPEGINTERFERON ALFA-2B.
5
Reports of Off label use with ROPEGINTERFERON ALFA-2B
38.5%
of all ROPEGINTERFERON ALFA-2B reports
1
Deaths
1
Hospitalizations
How Dangerous Is Off label use From ROPEGINTERFERON ALFA-2B?
Of the 5 reports, 1 (20.0%) resulted in death, 1 (20.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROPEGINTERFERON ALFA-2B. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does ROPEGINTERFERON ALFA-2B Cause?
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)